Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
GO-2032c Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
GO-2032c: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
DA-2811 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
DA-2811: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Umbilical cord derived mesenchymal stem cells(Wuhan Union Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Umbilical cord derived mesenchymal stem cells(Wuhan Union Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
AFA-281 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AFA-281: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SR-750 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
SR-750: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BD-111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
BD-111: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AFDX-0250BS Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AFDX-0250BS: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VX-407 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
VX-407: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HY-0902 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
HY-0902: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AGS-004 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AGS-004: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Memory cytokine-enriched NK cell therapy (ImmunityBio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Memory cytokine-enriched NK cell therapy (ImmunityBio): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
β-globin restored autologous hematopoietic stem cells (Hemogen Gene): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.